Representation of Envision Healthcare Corporation, Inc. in a DOJ/OIG investigation of allegations that allowing physician owners to share in anesthesia profits of Envision’s Folsom, California and Fresno, California ASCs violates the Anti-Kickback Statute.
Representation of Envision Healthcare Corporation, Inc. in DOJ/OIG Investigation
You Also May Be Interested In:
Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers
Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.